Literature DB >> 19069357

MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms.

Adisbeth Morales-Burgos1, Jorge L Sánchez, Luz D Figueroa, Wilfredo E De Jesús-Monge, Marcia R Cruz-Correa, Carmen González-Keelan, Cruz María Nazario.   

Abstract

BACKGROUND: Muir-Torre Syndrome (MTS) is a rare autosomal-dominant disorder characterized by the predisposition to both sebaceous neoplasm and internal malignancies. MTS-associated sebaceous neoplasms reveal mutations in DNA mismatch repair (MMR) genes and microsatellite instability. A significant part of MTS patients represents a phenotypic variant, the hereditary nonpolyposis colorectal cancer (HNPCC). A strong correlation between microsatellite instability and immunostaining has been demonstrated. The early recognition of sebaceous neoplasm as part of MTS, and their differentiation from sporadic sebaceous neoplasm may have an important application in a clinical setting. The absence of MLH-1 or MSH-2 expression by immunostaining identifies tumors with mismatch repair deficiency.
OBJECTIVES: Our aim is to determine whether an immunohistochemical approach, targeting DNA repair proteins MSH-2 and MLH-1 in MTS-related sebaceous neoplasm and their sporadic counterparts, can be used for their identification.
METHODS: We examined 15 sebaceous neoplasms (including 6 internal malignancy- associated sebaceous neoplasms and 8 sporadic sebaceous neoplasms) from 11 patients for the expression of MSH-2 and MLH-1 by immunohistochemistry.
RESULTS: Four of 5 internal malignancy-associated sebaceous neoplasms showed loss of expression of MSH-2 or MLH-1. Correlation of the immunostaining pattern of the sebaceous neoplasms and the patients' positive history of colon carcinoma was 80%. Seven of 8 sporadic sebaceous neoplasms showed a positive expression of MSH-2 and MLH-1. The prevalence for loss of expression of MMR proteins in sebaceous neoplasms was 38.5%. MMR immunostaining had 87.5% specificity and 80% sensitivity. LIMITATIONS: This study is limited by a small sample size, and by bias selection due to the use of non nationwide data-base as the resource of cases.
CONCLUSIONS: Our findings demonstrate that immunohistochemical testing for internal malignancy-associated sebaceous neoplasms is a practical approach to confirm a suspected inherited MMR gene defect, and an accurate method to distinguish between sporadic and MTS-associated sebaceous lesions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19069357      PMCID: PMC2680687     

Source DB:  PubMed          Journal:  P R Health Sci J        ISSN: 0738-0658            Impact factor:   0.705


  22 in total

1.  A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome.

Authors:  E Mangold; C Pagenstecher; M Leister; M Mathiak; A Rütten; W Friedl; P Propping; T Ruzicka; R Kruse
Journal:  J Med Genet       Date:  2004-07       Impact factor: 6.318

2.  The Muir-Torre (Torre's) syndrome: the significance of a solitary sebaceous tumor.

Authors:  J Rothenberg; W C Lambert; J T Vail; A S Nemlick; R A Schwartz
Journal:  J Am Acad Dermatol       Date:  1990-10       Impact factor: 11.527

3.  A novel germline mutation in the hMLH1 DNA mismatch repair gene in a patient with an isolated cystic sebaceous tumor.

Authors:  R Kruse; A Rütten; H R Malayeri; H J Günzl; W Friedl; P Propping
Journal:  J Invest Dermatol       Date:  1999-01       Impact factor: 8.551

4.  Multiple sebaceous tumors.

Authors:  D Torre
Journal:  Arch Dermatol       Date:  1968-11

5.  Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face.

Authors:  E G Muir; A J Bell; K A Barlow
Journal:  Br J Surg       Date:  1967-03       Impact factor: 6.939

6.  Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors.

Authors:  V A Marcus; L Madlensky; R Gryfe; H Kim; K So; A Millar; L K Temple; E Hsieh; T Hiruki; S Narod; B V Bapat; S Gallinger; M Redston
Journal:  Am J Surg Pathol       Date:  1999-10       Impact factor: 6.394

7.  Loss of mismatch repair proteins in sebaceous gland tumors.

Authors:  Nikolay K Popnikolov; Zoran Gatalica; Maria I Colome-Grimmer; Ramón L Sánchez
Journal:  J Cutan Pathol       Date:  2003-03       Impact factor: 1.587

8.  Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome.

Authors:  Pilar Machin; Lluis Catasus; Cristina Pons; Josefina Muñoz; Jose Maria Conde-Zurita; Judith Balmaña; Maria Barnadas; Rosa M Martí; Jaime Prat; Xavier Matias-Guiu
Journal:  J Cutan Pathol       Date:  2002-08       Impact factor: 1.587

Review 9.  The Muir-Torre syndrome: a 25-year retrospect.

Authors:  R A Schwartz; D P Torre
Journal:  J Am Acad Dermatol       Date:  1995-07       Impact factor: 11.527

10.  Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria.

Authors:  R Kruse; A Rütten; C Lamberti; H R Hosseiny-Malayeri; Y Wang; C Ruelfs; M Jungck; M Mathiak; T Ruzicka; W Hartschuh; M Bisceglia; W Friedl; P Propping
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

View more
  8 in total

Review 1.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

2.  Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico.

Authors:  Wilfredo E De Jesus-Monge; Carmen Gonzalez-Keelan; Ronghua Zhao; Stanley R Hamilton; Miguel Rodriguez-Bigas; Marcia Cruz-Correa
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

3.  Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.

Authors:  G Ponti; G Pellacani; C Ruini; A Percesepe; C Longo; V Desmond Mandel; F Crucianelli; G Gorelli; A Tomasi
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

4.  Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms.

Authors:  Maegan E Roberts; Douglas L Riegert-Johnson; Brittany C Thomas; Colleen S Thomas; Michael G Heckman; Murli Krishna; David J DiCaudo; Alina G Bridges; Katherine S Hunt; Kandelaria M Rumilla; Mark A Cappel
Journal:  J Genet Couns       Date:  2012-12-06       Impact factor: 2.537

5.  Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm.

Authors:  Jessica N Everett; Victoria M Raymond; Monica Dandapani; Monica Marvin; Wendy Kohlmann; Anu Chittenden; Erika Koeppe; Shanna L Gustafson; Tobias Else; Douglas R Fullen; Timothy M Johnson; Sapna Syngal; Stephen B Gruber; Elena M Stoffel
Journal:  JAMA Dermatol       Date:  2014-12       Impact factor: 10.282

6.  Comparison of universal screening in major lynch-associated tumors: a systematic review of literature.

Authors:  George Kunnackal John; Vipin Das Villgran; Christine Caufield-Noll; Francis M Giardiello
Journal:  Fam Cancer       Date:  2021-01-11       Impact factor: 2.375

Review 7.  The Mutator Phenotype: Adapting Microbial Evolution to Cancer Biology.

Authors:  Federica Natali; Giulia Rancati
Journal:  Front Genet       Date:  2019-08-06       Impact factor: 4.599

Review 8.  DNA mismatch repair system: repercussions in cellular homeostasis and relationship with aging.

Authors:  Juan Cristóbal Conde-Pérezprina; Miguel Ángel León-Galván; Mina Konigsberg
Journal:  Oxid Med Cell Longev       Date:  2012-11-08       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.